Malarone

Atovaquone, the active ingredient in Malarone, is an antiprotozoal (antimalarial) presented as an oral tablet for oral use. Combined with proguanil hydrochloride, it is used for the prevention of malaria infection and the treatment of acute, uncomplicated Plasmodium falciparum malaria in adults and children.\n\nGNH India supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, meeting EU standards and manufactured under strict GMP conditions.

Malarone is an antimalarial medication used to prevent and treat malaria caused by Plasmodium parasites.\n\n- Prevention of malaria (chemoprophylaxis): Provides prophylactic protection for travelers to endemic regions.\n- Treatment of acute uncomplicated Plasmodium falciparum malaria: Clears parasitaemia and resolves clinical symptoms.\n- Post‑exposure prophylaxis after potential malaria exposure: Reduces risk of infection when treatment is started shortly after a possible bite.

Common Side Effects:\n- Nausea: mild to moderate gastrointestinal upset.\n- Headache: transient cranial discomfort.\n- Abdominal pain: intermittent stomach discomfort.\n- Vomiting: occasional emesis after dosing.\n- Diarrhoea: loose stools, usually self‑limiting.\n- Loss of appetite: reduced desire to eat.\n\nSerious or Rare Side Effects:\n- Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention.\n- Hepatic enzyme elevations: may indicate liver stress.\n- Hemolysis in patients with G6PD deficiency: watch for dark urine and fatigue.\n- Anaphylaxis or severe allergic reactions: airway swelling, hypotension.\n- Neutropenia or agranulocytosis: increased infection risk.\n- Cardiovascular abnormalities (e.g., QT prolongation): monitor in susceptible individuals.

Malarone should be used with caution in specific clinical situations.\n\n- Pregnancy: consult a healthcare professional before use.\n- Breastfeeding: discuss potential risks with a physician.\n- Renal impairment: dose adjustment may be required.\n- Hepatic impairment: monitor liver function during therapy.\n- G6PD deficiency: increased risk of hemolysis; avoid if possible.\n- Known resistance: avoid in regions with documented atovaquone‑proguanil resistance.\n- Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Malarone may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.\n\nMajor Interactions (Avoid):\n- Rifampin: markedly lowers atovaquone and proguanil plasma levels.\n- Protease inhibitors (e.g., ritonavir): can increase drug concentrations, raising toxicity risk.\n- Strong CYP2C8 inhibitors (e.g., gemfibrozil): elevate atovaquone exposure.\n- Macrolide antibiotics (e.g., erythromycin): may increase proguanil levels.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: may enhance anticoagulant effect; monitor INR.\n- Anticonvulsants (e.g., carbamazepine, phenytoin): can reduce drug levels.\n- Oral contraceptives: possible reduction in contraceptive efficacy; consider additional protection.